X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (49) 49
oncology (40) 40
humans (35) 35
female (22) 22
male (22) 22
middle aged (19) 19
mutation (19) 19
protein kinase inhibitors - therapeutic use (15) 15
cancer (14) 14
aged (13) 13
carcinoma, non-small-cell lung - drug therapy (13) 13
carcinoma, non-small-cell lung - genetics (12) 12
lung neoplasms - genetics (12) 12
lung neoplasms - pathology (12) 12
respiratory system (12) 12
adult (11) 11
carcinoma, non-small-cell lung - pathology (11) 11
immunotherapy (11) 11
lung neoplasms - drug therapy (11) 11
cell lung-cancer (10) 10
crizotinib (10) 10
chemotherapy (9) 9
resistance (9) 9
antineoplastic agents - therapeutic use (8) 8
hematology, oncology and palliative medicine (8) 8
lung cancer, non-small cell (8) 8
open-label (8) 8
adenocarcinoma (7) 7
alectinib (7) 7
article (7) 7
gastric cancer (7) 7
neoplasm staging (7) 7
nsclc (7) 7
prognosis (7) 7
pyridines - therapeutic use (7) 7
acquired-resistance (6) 6
adenocarcinoma - pathology (6) 6
care and treatment (6) 6
disease progression (6) 6
gastroenterology & hepatology (6) 6
genomic profiling (6) 6
lung cancer (6) 6
pulmonary/respiratory (6) 6
pyrazoles - therapeutic use (6) 6
receptor protein-tyrosine kinases - genetics (6) 6
review (6) 6
tumors (6) 6
tyrosine kinase inhibitor (6) 6
biopsy (5) 5
brain neoplasms - drug therapy (5) 5
brain neoplasms - secondary (5) 5
comprehensive genomic profiling (5) 5
double-blind (5) 5
genetic aspects (5) 5
medical colleges (5) 5
molecular targeted therapy (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
next-generation sequencing (5) 5
radiation (5) 5
targeted therapy (5) 5
treatment outcome (5) 5
biomarkers, tumor - genetics (4) 4
cancer therapies (4) 4
carcinoma (4) 4
drug resistance, neoplasm - genetics (4) 4
gastrointestinal cancer (4) 4
gene expression regulation, neoplastic (4) 4
genomics - methods (4) 4
heterogeneity (4) 4
high-throughput nucleotide sequencing (4) 4
lung neoplasms - metabolism (4) 4
metastasis (4) 4
mutation - genetics (4) 4
mutations (4) 4
patients (4) 4
pembrolizumab (4) 4
receptor protein-tyrosine kinases - metabolism (4) 4
stomach cancer (4) 4
survival (4) 4
therapy (4) 4
tumor mutational burden (4) 4
adenocarcinoma - genetics (3) 3
anaplastic lymphoma kinase (3) 3
biomarker (3) 3
brain metastases (3) 3
breast-cancer (3) 3
cancer patients (3) 3
carbazoles - therapeutic use (3) 3
carcinoma, non-small-cell lung - enzymology (3) 3
ceritinib (3) 3
circulating tumor dna (3) 3
colon cancer (3) 3
colorectal cancer (3) 3
crizotinib resistance (3) 3
development and progression (3) 3
dna mutational analysis (3) 3
drug resistance, neoplasm (3) 3
egfr (3) 3
epidermal growth factor (3) 3
esophageal cancer (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


TRANSLATIONAL CANCER RESEARCH, ISSN 2218-676X, 08/2018, Volume 7, pp. S806 - S809
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2019, Volume 20, Issue 8, pp. 1041 - 1043
Journal Article
Cancer Discovery, ISSN 2159-8274, 01/2020, Volume 10, Issue 1, pp. 20 - 22
Journal Article
Gastroenterology, ISSN 0016-5085, 05/2019, Volume 156, Issue 6, pp. S-100 - S-100
Journal Article
Cancer discovery, ISSN 2159-8274, 02/2019, Volume 9, Issue 2, pp. 166 - 168
Sanchez-Vega and colleagues prospectively demonstrate that both intra-and intertumoral differential expression of the receptor tyrosine kinases HER2, EGFR, and... 
HETEROGENEITY | RESISTANCE | THERAPY | ONCOLOGY
Journal Article
Gastroenterology, ISSN 0016-5085, 06/2019, Volume 156, Issue 8, pp. 2242 - 2253.e4
It has been a challenge to select treatment for patients with pancreatic ductal adenocarcinomas (PDACs) based on genome alterations. We performed targeted... 
Metastatic | IPMN | Locally Advanced | MAPK | SURVIVAL | MULTICENTER | LANDSCAPE | SEQUENCE VARIANTS | PRECISION MEDICINE | OPEN-LABEL | REARRANGEMENTS | GEMCITABINE | CANCER GENES | MUTATIONS | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 11/2019, Volume 14, Issue 11, pp. 1875 - 1877
Journal Article
World Journal of Gastroenterology, ISSN 1007-9327, 07/2018, Volume 24, Issue 25, pp. 2686 - 2697
Blockade of the programmed death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) receptor axis represents an effective form of cancer immunotherapy.... 
Microsatellite instablility | Programmed death ligand 1 | Gastric cancer | Immunotherapy | Programmed cell death 1 | PD-L1 EXPRESSION | CD4+AND CD8+T CELLS | ANTI-PD-L1 ANTIBODY | GASTRIC-CANCER | B7 FAMILY | B7-H1 | GASTROENTEROLOGY & HEPATOLOGY | EPSTEIN-BARR-VIRUS | MISMATCH REPAIR DEFICIENCY | TUMOR MICROENVIRONMENT | T-CELLS | Minireviews
Journal Article
Gut, ISSN 0017-5749, 08/2019, p. gutjnl-2019-318325
While oesophageal squamous cell carcinoma remains infrequent in Western populations, the incidence of oesophageal adenocarcinoma (EAC) has increased sixfold to... 
Journal Article
The Oncologist, ISSN 1083-7159, 11/2019, Volume 24, Issue 11, pp. 1462 - 1468
Background With the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited... 
Receptor tyrosine kinase | Heterogeneity | Gastric cancer | Fibroblast growth factor receptor 2 | Gastroesophageal junction adenocarcinoma
Journal Article
The Oncologist, ISSN 1083-7159, 01/2020, Volume 25, Issue 1, pp. e147 - e159
Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the... 
Neoplasm | DNA mutational analysis | Genes | DNA | Programmed cell death 1 receptor | Sequence analysis | Antibodies/therapeutic use
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 4335 - 4335
Journal Article
The Oncologist, ISSN 1083-7159, 04/2019, Volume 24, Issue 4, pp. 475 - 482
Background The randomized phase III RAINBOW trial established paclitaxel (pac) plus ramucirumab (ram) as a global standard for second‐line (2L) therapy in... 
Second line | Ramucirumab | GEJ adenocarcinoma | Gastric cancer | FOLFIRI | MULTICENTER PHASE-II | JUNCTION CANCER | OPEN-LABEL | CHEMOTHERAPY | CAPECITABINE | HETEROGENEITY | CISPLATIN | ONCOLOGY | ADVANCED GASTRIC-CANCER | DOUBLE-BLIND | 1ST-LINE THERAPY | Index Medicus | Gastrointestinal Cancer
Journal Article
Gastroenterology, ISSN 0016-5085, 04/2017, Volume 152, Issue 5, pp. S1209 - S1209
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2017, Volume 12, Issue 12, pp. 1857 - 1858
Journal Article
Journal of Carcinogenesis, ISSN 0974-6773, 04/2017, Volume 16, Issue 1, pp. 3 - 3
African Americans and Hispanics are reported to have higher mortality from esophageal cancer (EC) than Caucasians. In this study, we analyzed the independent... 
ethnicity | race | outcomes | Esophageal cancer | survival disparity
Journal Article
The Oncologist, ISSN 1083-7159, 01/2020, Volume 25, Issue 1, pp. e39 - e47
Purpose Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in multiple tumor types (e.g. HER2 in breast cancer), and amplification of... 
amplification | PDGFRA | genomic profiling | sarcoma | tyrosine kinase inhibitor | KIT | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.